1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
End-of-day quote Korea Stock Exchange  -  05-19
808000.00 KRW   +1.51%
03:38aSAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies; SK Hynix Loses 2%
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

S.Korea stocks hit 7-week closing low ahead of LGES IPO

01/18/2022 | 02:10am EDT

* KOSPI falls, foreigners net buyers

* Korean won strengthens against U.S. dollar

* South Korea benchmark bond yield falls

* For the midday report, please click

SEOUL, Jan 18 (Reuters) - Round-up of South Korean financial markets:

** South Korean shares ended at their lowest level in seven weeks on Tuesday, extending the selling spree for a fourth day, as investors reduced their positions ahead of LG Energy Solution's $10.8 billion initial public offering and the U.S. Federal Reserve policy meeting later this month.

** The Korean won strengthened, while the benchmark bond yield fell.

** The benchmark KOSPI closed down 25.86 points, or 0.89%, at 2,864.24, the lowest since Nov. 30.

** Chip giants Samsung Electronics and SK Hynix fell 0.65% and 0.39%, respectively, leading the declines, while Samsung Biologics also slid 2.42%.

** Battery maker LG Energy Solution's public subscription for retail investors takes place on Tuesday and Wednesday, after institutional investors placed bids that were valued at record $12.8 trillion.

** U.S. Treasury yields continued to gain, with the short end of the curve hitting new pandemic highs, as expectations of hawkish stance at the Fed's upcoming meeting strengthened.

** On the main board, institutional investors sold net 225.9 billion won ($189.76 million) worth of shares, offsetting net buying of 214.3 billion won worth of shares by retail and foreign investors.

** The won ended at 1,190.1 per dollar on the onshore settlement platform, 0.22% higher than its previous close.

** In offshore trading, the won was quoted at 1,190.3 per dollar, unchanged from the previous day, while in non-deliverable forward trading its one-month contract was quoted at 1,190.9.

** In money and debt markets, March futures on three-year treasury bonds rose 0.06 point to 108.04.

** The most liquid 3-year Korean treasury bond yield fell by 1.7 basis points to 2.131%, while the benchmark 10-year yield fell by 0.5 basis point to 2.563%. ($1 = 1,190.4800 won) (Reporting by Joori Roh; Editing by Shounak Dasgupta)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
KOSPI COMPOSITE INDEX 0.20% 2643.92 Real-time Quote.-11.35%
LG CHEM, LTD. 8.57% 545000 End-of-day quote.-11.38%
NAVER CORPORATION 1.29% 275000 End-of-day quote.-27.34%
ON SEMICONDUCTOR CORPORATION -1.35% 55.79 Delayed Quote.-16.87%
SAMSUNG BIOLOGICS CO.,LTD. 1.51% 808000 End-of-day quote.-10.52%
SAMSUNG ELECTRONICS CO., LTD. 0.74% 68000 End-of-day quote.-13.15%
SK HYNIX INC. 1.35% 112500 End-of-day quote.-14.12%
All news about SAMSUNG BIOLOGICS CO.,LTD.
03:38aSAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies..
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 3..
CI
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
04/28Samsung Biologics' Net Income Surges 141% in March Quarter
MT
04/28Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
04/27SAMSUNG BIOLOGICS : Material Business Matters Related to Investment Decisions
PU
04/21SAMSUNG BIOLOGICS : Results of issuance (Voluntary Disclosure)
PU
04/05Allakos Inc. Enters into A Master Development Services Agreement with Samsung Biologics..
CI
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2022 1 991 B 1,56 B 1,56 B
Net income 2022 542 B 0,43 B 0,43 B
Net Debt 2022 566 B 0,44 B 0,44 B
P/E ratio 2022 104x
Yield 2022 -
Capitalization 58 292 B 45 781 M 45 781 M
EV / Sales 2022 29,6x
EV / Sales 2023 25,9x
Nbr of Employees 2 886
Free-Float 25,6%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 819 000,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Doyoung Heo Head-Finance & Vice President
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 166
CSL LIMITED-5.35%93 148
WUXI BIOLOGICS (CAYMAN) INC.-39.17%30 261
BIOGEN INC.-16.78%29 239
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%22 130
UCB-13.28%17 367